1. Home
  2. PFS vs GERN Comparison

PFS vs GERN Comparison

Compare PFS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFS
  • GERN
  • Stock Information
  • Founded
  • PFS 1839
  • GERN 1990
  • Country
  • PFS United States
  • GERN United States
  • Employees
  • PFS N/A
  • GERN N/A
  • Industry
  • PFS Savings Institutions
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • PFS Finance
  • GERN Health Care
  • Exchange
  • PFS Nasdaq
  • GERN Nasdaq
  • Market Cap
  • PFS 2.5B
  • GERN 2.5B
  • IPO Year
  • PFS N/A
  • GERN 1996
  • Fundamental
  • Price
  • PFS $19.05
  • GERN $3.49
  • Analyst Decision
  • PFS Strong Buy
  • GERN Strong Buy
  • Analyst Count
  • PFS 5
  • GERN 10
  • Target Price
  • PFS $22.60
  • GERN $7.05
  • AVG Volume (30 Days)
  • PFS 622.8K
  • GERN 7.6M
  • Earning Date
  • PFS 01-23-2025
  • GERN 11-07-2024
  • Dividend Yield
  • PFS 5.04%
  • GERN N/A
  • EPS Growth
  • PFS N/A
  • GERN N/A
  • EPS
  • PFS 0.98
  • GERN N/A
  • Revenue
  • PFS $526,013,000.00
  • GERN $29,480,000.00
  • Revenue This Year
  • PFS N/A
  • GERN $32,021.10
  • Revenue Next Year
  • PFS $27.36
  • GERN $298.14
  • P/E Ratio
  • PFS $19.47
  • GERN N/A
  • Revenue Growth
  • PFS 13.26
  • GERN 9199.68
  • 52 Week Low
  • PFS $13.07
  • GERN $1.64
  • 52 Week High
  • PFS $22.24
  • GERN $5.34
  • Technical
  • Relative Strength Index (RSI)
  • PFS 36.90
  • GERN 29.57
  • Support Level
  • PFS $20.07
  • GERN $3.75
  • Resistance Level
  • PFS $20.78
  • GERN $4.00
  • Average True Range (ATR)
  • PFS 0.59
  • GERN 0.17
  • MACD
  • PFS -0.27
  • GERN -0.04
  • Stochastic Oscillator
  • PFS 18.70
  • GERN 5.51

About PFS Provident Financial Services Inc

Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: